{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:24:39Z","timestamp":1648718679497},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T00:00:00Z","timestamp":1342656000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00011-012-0521-z","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T01:06:29Z","timestamp":1342659989000},"page":"1241-1246","source":"Crossref","is-referenced-by-count":0,"title":["Serum vitronectin levels in patients with Beh\u00e7et\u2019s disease"],"prefix":"10.1007","volume":"61","author":[{"given":"Ali","family":"Yal\u00e7\u0131nda\u011f","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asl\u0131han","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nil\u00fcfer Yal\u00e7\u0131nda\u011f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam\u0131k","family":"Deliba\u015f","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,19]]},"reference":[{"key":"521_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/107602960501100107","volume":"11","author":"H Ekmekci","year":"2005","unstructured":"Ekmekci H, Ekmekci OB, Sonmez H, Ozturk Z, Domanic N, Kokoglu E. Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis. Clin Appl Thromb Hemost. 2005;11:63\u201370.","journal-title":"Clin Appl Thromb Hemost"},{"key":"521_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cca.2005.12.015","volume":"368","author":"OB Ekmekci","year":"2006","unstructured":"Ekmekci OB, Ekmekci H. Vitronectin in atherosclerotic disease. Clin Chim Acta. 2006;368:77\u201383.","journal-title":"Clin Chim Acta"},{"key":"521_CR3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1538-7836.2005.01217.x","volume":"3","author":"A Reheman","year":"2005","unstructured":"Reheman A, Gross P, Yang H, Chen P, Allen D, Leytin V, Freedman J, Ni H. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost. 2005;3:875\u201383.","journal-title":"J Thromb Haemost"},{"key":"521_CR4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/A:1025000810466","volume":"14","author":"H Ekmekci","year":"2002","unstructured":"Ekmekci H, Sonmez H, Ekmekci OB, Ozturk Z, Domanic N, Kokoglu E. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis. 2002;14:221\u20135.","journal-title":"J Thromb Thrombolysis"},{"key":"521_CR5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.V93.6.1825.406k37_1825_1830","volume":"93","author":"WP Fay","year":"1999","unstructured":"Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood. 1999;93:1825\u201330.","journal-title":"Blood"},{"key":"521_CR6","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1111\/j.1538-7836.2005.01479.x","volume":"3","author":"S Koschnick","year":"2005","unstructured":"Koschnick S, Konstantinides S, Schafer K, Crain K, Loskutoff DJ. Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. J Thromb Haemost. 2005;3:2290\u20135.","journal-title":"J Thromb Haemost"},{"key":"521_CR7","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1161\/01.CIR.103.4.576","volume":"103","author":"S Konstantinides","year":"2001","unstructured":"Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001;103:576\u201383.","journal-title":"Circulation"},{"key":"521_CR8","doi-asserted-by":"crossref","first-page":"19788","DOI":"10.1074\/jbc.M908079199","volume":"275","author":"TJ Podor","year":"2000","unstructured":"Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem. 2000;275:19788\u201394.","journal-title":"J Biol Chem"},{"key":"521_CR9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nsb943","volume":"10","author":"A Zhou","year":"2003","unstructured":"Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol. 2003;10:541\u20134.","journal-title":"Nat Struct Biol"},{"key":"521_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(97)00298-3","volume":"89","author":"KT Preissner","year":"1998","unstructured":"Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res. 1998;89:1\u201321.","journal-title":"Thromb Res"},{"key":"521_CR11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1751-553X.2008.01107.x","volume":"31","author":"F Newall","year":"2009","unstructured":"Newall F, Johnston L, Ignjatovic V, Summerhayes R, Monagle P. Age-related reference ranges for two heparin-binding proteins: vitronectin and platelet factor 4. Int J Lab Hematol. 2009;31:683\u20137.","journal-title":"Int J Lab Hematol"},{"key":"521_CR12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/ajcp\/96.5.605","volume":"96","author":"H Mohri","year":"1991","unstructured":"Mohri H, Ohkubo T. How vitronectin binds to activated glycoprotein IIb-IIIa complex and its function in platelet aggregation. Am J Clin Pathol. 1991;96:605\u20139.","journal-title":"Am J Clin Pathol"},{"key":"521_CR13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jcp.22356","volume":"226","author":"AS Antonov","year":"2011","unstructured":"Antonov AS, Antonova GN, Munn DH, Mivechi N, Lucas R, Catravas JD, Verin AD. \u03b1V\u03b23 integrin regulates macrophage inflammatory responses via PI3 kinase\/Akt-dependent NF-\u03baB activation. J Cell Physiol. 2011;226:469\u201376.","journal-title":"J Cell Physiol"},{"issue":"5","key":"521_CR14","doi-asserted-by":"crossref","first-page":"e37195","DOI":"10.1371\/journal.pone.0037195","volume":"7","author":"R Li","year":"2012","unstructured":"Li R, Ren M, Chen N, Luo M, Zhang Z, Wu J. Vitronectin increases vascular permeability by promoting VE-cadherin internalization at cell junctions. PLoS One. 2012;7(5):e37195.","journal-title":"PLoS One"},{"key":"521_CR15","first-page":"1078","volume":"335","author":"International Study Group for Behcet\u2019s disease","year":"1990","unstructured":"International Study Group for Behcet\u2019s disease. Criteria for diagnosis of Behcet\u2019s disease. Lancet. 1990;335:1078\u201380.","journal-title":"Lancet"},{"key":"521_CR16","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/bjo.2009.161018","volume":"93","author":"M Citirik","year":"2009","unstructured":"Citirik M, Haznedaroglu IC, Teberik K, Soykan E, Zilelioglu O. Basic parameters of thrombophilia in ocular Behcet disease with posterior segment involvement. Br J Ophthalmol. 2009;93:1382\u20136.","journal-title":"Br J Ophthalmol"},{"key":"521_CR17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00415-010-5885-9","volume":"258","author":"D Aguiar de Sousa","year":"2011","unstructured":"Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet\u2019s disease: a systematic review. J Neurol. 2011;258:719\u201327.","journal-title":"J Neurol"},{"key":"521_CR18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s10067-010-1455-x","volume":"29","author":"NS Yasar","year":"2010","unstructured":"Yasar NS, Salgur F, Cansu DU, Kasifoglu T, Korkmaz C. Combined thrombophilic factors increase the risk of recurrent thrombotic events in Behcet\u2019s disease. Clin Rheumatol. 2010;29:1367\u201372.","journal-title":"Clin Rheumatol"},{"key":"521_CR19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0049-3848(02)00006-3","volume":"105","author":"S Kiraz","year":"2002","unstructured":"Kiraz S, Ertenli I, Ozturk MA, Haznedaroglu IC, Celik I, Calguneri M. Pathological haemostasis and prothrombotic state in Behcet\u2019s disease. Thromb Res. 2002;105:125\u201333.","journal-title":"Thromb Res"},{"key":"521_CR20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3899\/jrheum.100257","volume":"38","author":"B Krupa","year":"2011","unstructured":"Krupa B, Cimaz R, Ozen S, Fischbach M, Cochat P, Kone-Paut I. Pediatric Behcet\u2019s disease and thromboses. J Rheumatol. 2011;38:387\u201390.","journal-title":"J Rheumatol"},{"key":"521_CR21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2003.12.010","volume":"137","author":"K Probst","year":"2004","unstructured":"Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behcet\u2019s disease. Am J Ophthalmol. 2004;137:850\u20137.","journal-title":"Am J Ophthalmol"},{"key":"521_CR22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.thromres.2010.05.019","volume":"126","author":"A Donmez","year":"2010","unstructured":"Donmez A, Aksu K, Ayd\u0131n H, Keser G, Cagirgan S, Doganavsargil E, Tombuloglu M. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behcet disease and their association with thrombosis. Thromb Res. 2010;126:207\u201310.","journal-title":"Thromb Res"},{"key":"521_CR23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.thromres.2004.09.010","volume":"115","author":"A Donmez","year":"2005","unstructured":"Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Ayd\u0131n HH, Tombuloglu M, Doganavsargil E. Thrombin activatable fibrinolysis inhibitor in Behcet\u2019s disease. Thromb Res. 2005;115:287\u201392.","journal-title":"Thromb Res"},{"key":"521_CR24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000318601","volume":"225","author":"M Citirik","year":"2011","unstructured":"Citirik M, Berker N, Songur MS, Ozkan SS, Zilelioglu O. Ocular manifestations of late-onset Behcet disease. Ophthalmologica. 2011;225:21\u20136.","journal-title":"Ophthalmologica"},{"key":"521_CR25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1756-185X.2010.01462.x","volume":"13","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Sadeghi Abdollahi B. How to deal with Behcet\u2019s disease in daily practice. Int J Rheum Dis. 2010;13:105\u201316.","journal-title":"Int J Rheum Dis"},{"key":"521_CR26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.thromres.2011.03.003","volume":"128","author":"S Birengel","year":"2011","unstructured":"Birengel S, Yalcindag FN, Yalcindag A, Sahli E, Batioglu F. Urokinase plasminogen activator receptor levels in Behcet\u2019s disease. Thromb Res. 2011;128:274\u20136.","journal-title":"Thromb Res"},{"key":"521_CR27","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0002-9343(01)01048-8","volume":"112","author":"G Espinosa","year":"2002","unstructured":"Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC. Vascular involvement in Behcet\u2019s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37\u201343.","journal-title":"Am J Med"},{"key":"521_CR28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1076029606293430","volume":"12","author":"S Akar","year":"2006","unstructured":"Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan GH, Akkoc N, Ozkan S, Demirkan F, Onen F. Circulated activated platelets and increased platelet reactivity in patients with Behcet\u2019s disease. Clin Appl Thromb Hemost. 2006;12:451\u20137.","journal-title":"Clin Appl Thromb Hemost"},{"key":"521_CR29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/BOR.0b013e32831de4e7","volume":"21","author":"G Tomasson","year":"2009","unstructured":"Tomasson G, Monach PA, Merkel PA. Thromboembolic disease in vasculitis. Curr Opin Rheumatol. 2009;21:41\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"521_CR30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1620\/tjem.221.119","volume":"221","author":"N Acikgoz","year":"2010","unstructured":"Acikgoz N, Karincaoglu Y, Ermis N, Yagmur J, Atas H, Kurtoglu E, Cansel M, Barutcu I, Pekdemir H, Ozdemir R. Increased mean platelet volume in Behcet\u2019s disease with thrombotic tendency. Tohoku J Exp Med. 2010;221:119\u201323.","journal-title":"Tohoku J Exp Med"},{"key":"521_CR31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1378\/chest.118.2.479","volume":"118","author":"N Mogulkoc","year":"2000","unstructured":"Mogulkoc N, Burgess MI, Bishop PW. Intracardiac thrombus in Behcet\u2019s disease: a systematic review. Chest. 2000;118:479\u201387.","journal-title":"Chest"},{"key":"521_CR32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1046\/j.1365-4362.2003.01688.x","volume":"42","author":"M Cekmen","year":"2003","unstructured":"Cekmen M, Evereklioglu C, Er H, Inaloz HS, Doganay S, Turkoz Y, Ozerol IH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behcet\u2019s syndrome. Int J Dermatol. 2003;42:870\u20135.","journal-title":"Int J Dermatol"},{"key":"521_CR33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-2141.2008.07078.x","volume":"141","author":"JM Ricart","year":"2008","unstructured":"Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol. 2008;141:716\u20139.","journal-title":"Br J Haematol"},{"key":"521_CR34","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00417-008-0873-9","volume":"246","author":"FN Yalcindag","year":"2008","unstructured":"Yalcindag FN, Batioglu F, Ozdemir O, Cansizoglu E, Egin Y, Akar N. Soluble endothelial protein C receptor levels in Beh\u00e7et patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol. 2008;246:1603\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"521_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MD.0b013e318211bf28","volume":"90","author":"H Ideguchi","year":"2011","unstructured":"Ideguchi H, Suda A, Takeno M, Ueda A, Ohno S, Ishigatsubo Y. Behcet disease: evolution of clinical manifestations. Medicine (Baltimore). 2011;90:125\u201332.","journal-title":"Medicine (Baltimore)"},{"key":"521_CR36","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-010-1430-6","volume":"29","author":"F Davatchi","year":"2010","unstructured":"Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridar A, Ashofteh F, Sadeghi Abdollahi B. Behcet\u2019s disease: from east to west. Clin Rheumatol. 2010;29:823\u201333.","journal-title":"Clin Rheumatol"},{"key":"521_CR37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/09273948.2011.555592","volume":"19","author":"L Atmaca","year":"2011","unstructured":"Atmaca L, Boyvat A, Yalcindag FN, Atmaca-Sonmez P, Gurler A. Behcet disease in children. Ocul Immunol Inflamm. 2011;19:103\u20137.","journal-title":"Ocul Immunol Inflamm"},{"key":"521_CR38","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-3848(97)00063-7","volume":"86","author":"S Guermazi","year":"1997","unstructured":"Guermazi S, Hamza M, Dellagi K. Protein S deficiency and antibodies to protein S in patients with Behcet\u2019s disease. Thromb Res. 1997;86:197\u2013204.","journal-title":"Thromb Res"},{"key":"521_CR39","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2004.05072.x","volume":"126","author":"S Navarro","year":"2004","unstructured":"Navarro S, Ricart JM, Medina P, Vaya A, Villa P, Todoli J, Estelles A, Mico ML, Aznar J, Espana F. Activated protein C levels in Behcet\u2019s disease and risk of venous thrombosis. Br J Haematol. 2004;126:550\u20136.","journal-title":"Br J Haematol"},{"key":"521_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1648128","volume":"67","author":"O Chafa","year":"1992","unstructured":"Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benebadji M. Behcet syndrome associated with protein S deficiency. Thromb Haemost. 1992;67:1\u20133.","journal-title":"Thromb Haemost"},{"key":"521_CR41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1365-4362.1998.00114.x","volume":"37","author":"N Lenk","year":"1998","unstructured":"Lenk N, Ozet G, Alli N, Coban O, Erbasi S. Protein C and protein S activities in Behcet\u2019s disease as risk factors of thrombosis. Int J Dermatol. 1998;37:124\u20135.","journal-title":"Int J Dermatol"},{"key":"521_CR42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/030006059802600405","volume":"26","author":"M Nalcaci","year":"1998","unstructured":"Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behcet\u2019s disease. J Int Med Res. 1998;26:206\u20138.","journal-title":"J Int Med Res"},{"key":"521_CR43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s00296-003-0324-1","volume":"24","author":"MA Ozturk","year":"2004","unstructured":"Ozturk MA, Ertenli I, Kiraz S, Haznedaroglu IC, Celik I, Kirazli S, Calguneri M. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet\u2019s disease. Rheumatol Int. 2004;24:98\u2013102.","journal-title":"Rheumatol Int"},{"key":"521_CR44","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCINTERVENTIONS.108.795799","volume":"2","author":"W Derer","year":"2009","unstructured":"Derer W, Barnathan ES, Safak E, Agarwal P, Heidecke H, M\u00f6ckel M, Gross M, Ozcelik C, Dietz R, Dechend R. Vitronectin concentrations predict risk in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2009;2:14\u20139.","journal-title":"Circ Cardiovasc Interv"},{"key":"521_CR45","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/01.CIR.96.6.1809","volume":"96","author":"M Gawaz","year":"1997","unstructured":"Gawaz M, Neumann FJ, Dickfeld T, Reininger A, Adelsberger H, Gebhardt A, Schomig A. Vitronectin receptor (alpha(v)beta3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation. 1997;96:1809\u201318.","journal-title":"Circulation"},{"key":"521_CR46","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/emboj\/18.4.882","volume":"18","author":"R Soldi","year":"1999","unstructured":"Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J. 1999;18:882\u201392.","journal-title":"EMBO J"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-012-0521-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00011-012-0521-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-012-0521-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T03:47:10Z","timestamp":1594439230000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00011-012-0521-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,19]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["521"],"URL":"https:\/\/doi.org\/10.1007\/s00011-012-0521-z","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,19]]}}}